

# Index

## A

- $\alpha_1$ -antagonists 63, 178
- 5- $\alpha$ -reductase inhibitors 179
- abatacept 211–12
- abciximab 70
- absorption
  - analgesia 232
  - antimicrobial therapy 115, 118
  - drug interactions 291–2
  - elderly patients 253
  - pharmacokinetics 5–6
  - pregnancy 256
- abuse of psychoactive drugs 108–10, 182
  - see also* substance use disorders
- acamprosate 109
- accidental ingestion 269
- ACE *see* angiotensin-converting enzyme
- acetaminophen 230
- aciclovir 130
- acquired immunity 204–5
- acquired immunodeficiency syndrome *see* HIV/AIDS
- ACS *see* acute coronary syndromes
- ACTH *see* adrenocorticotropic hormone
- actinomycin 189
- activated charcoal 273, 276, 282
- activated partial thromboplastin time (APTT) 218
- active immunisation 144, 146
- active secretion 10
- acute airways disease 76
- acute asthma 77
- acute chronic obstructive pulmonary disease (COPD) 77
- acute coronary syndromes (ACS) 29–34, 70
- acute left ventricular failure 285
- acute myocardial infarction 223
- acute oxygen therapy 78
- acute urinary retention (AUR) 178
- adalimumab 212–13
- adaptive immunity 204–5
- adenine nucleotides 42
- adenosine 42, 284–5
- adherence to therapy
  - antiretrovirals 140–1
  - dosage individualisation 241
  - prescribing practice 292–3
- adjuvant chemotherapy 186, 195–6
- adjuvant pain relief 229
- ADME *see* pharmacokinetics
- adrenal cortex disease 167–8
- adrenal steroid replacement 168
- adrenal suppression 209–10
- adrenaline 283, 284
- adrenergic  $\alpha$ -agonists 178
- adrenoceptor agonists 48
- adrenocorticotropic hormone (ACTH) 208–10
- ADT *see* androgen deprivation therapy
- adverse drug reactions
  - analgesia 229
  - antimicrobial therapy 115–18, 120–2, 124–30
  - antiretrovirals 135–9
  - blood conditions 218–19, 221–2, 224
  - chemotherapy 190, 195
  - coronary artery disease 30–1, 33, 37–42, 44, 46–8
  - dose–response relationships 5
  - endocrine disease 156–8, 161–8
  - gastrointestinal disease 19–24, 26–7
  - hypertension 57–60, 62, 66–9
  - immunopharmacology 207, 209
  - inflammatory joint disease 198, 200–1, 203
  - neurological disease 83–6, 88, 94
  - prescribing practice 289
  - psychiatric disorders 97–107, 109
  - renal disease 249
  - reproductive system 170–2, 175–7
  - respiratory disease 72–5, 78
  - toxicology 274
  - urological system 178–83
- AED *see* anti-epileptic drugs
- afferent neurons 228
- afterload 44, 49
- age of patient 112–13
- agitation 274
- agomelatine 103
- agonists 4–5
- agranulocytosis 161
- AIDS *see* HIV/AIDS
- alcohol 191
  - withdrawal 274
- aldosterone antagonists 47
- alefacept 212
- alendronate 165
- alfentanil 233
- alginatesan 19–20
- alkalosis 250–1
- alkylating agents 188
- allergic reactions *see* hypersensitivity reactions
- allopurinol 191, 203
- alopecia 190

- alteplase 223
- Alzheimer's disease 110
- amantidine 94, 95–6, 131
- amiloride 45
- aminoglycosides 115, 117, 120–1
- aminosalicylates 26–7
- aminosteroids 237
- amiodarone 38–9, 284
- amitriptyline 25, 88, 101–2
- amlodipine 31–2, 58
- amoxicillin 23
- amphetamines 281
- amphotericin B 117, 128
- amyl nitrates 182
- anaemia 137, 223–7
- anaesthesia 228, 233–7
- analgesia 228–33
  - adjuvant pain relief 229, 233
  - inflammatory joint disease 197–8
  - non-opioid analgesics 229, 230
  - opioids 229, 230–3
  - overdose 278–81
  - pathophysiology of pain 228
  - principles 229
  - WHO analgesic ladder 229
- anaphylaxis 283–4
- androgen deprivation therapy (ADT) 181
- angina pectoris 29–34
  - drugs used in treatment 30–3
  - management principles 33
  - stable angina 29–30, 33–4
  - unstable angina 30, 34
- angiotensin receptor blockers (ARB) 45, 46–8, 50, 56, 60–1
- angiotensin-converting enzyme (ACE) inhibitors
  - coronary artery disease 33, 45–8, 50
  - diabetes mellitus 154
  - hypertension 55–6, 59–60
  - neurological disease 89
  - pregnancy 256, 259
- anidulofungin 130
- animal studies 12
- ankylosing spondylitis (AS) 197
- antacids 19–20
- antagonists 4–5
- anthracyclines 189
- anti-androgens 177, 181
- anti-arrhythmic drugs 35–42
- antibacterials 113–15, 117–26
- antibiotics 20, 23, 28
- antibody-mediated hypersensitivity 205
- anticholinergic drugs
  - gastrointestinal disease 23
  - neurological disease 94, 96
  - respiratory disease 73
  - urological system 180
- anticoagulants 217–23
- anticonvulsants 258
- antidepressants
  - psychiatric disorders 97, 100–3
  - toxicology 276–8
  - see also individual drugs and drug classes*
- anti-emetics 87–8
- anti-epileptic drugs (AED) 82–7, 258
- antiepileptics 282
- antifungal drugs 128–30
- antihistamines 23, 214
- antihypertensive drugs 55–63
- anti-IgE therapy 76
- anti-inflammatory drugs 197
- antimetabolites 188
- antimicrobial therapy 111–31
  - bacterial infections 113–15, 117–26
  - drug-related factors 111, 115–17
  - fungal infections 114, 128–30
  - gastrointestinal disease 20, 23, 28
  - malignancies 189
  - management principles 111–17
  - microbiological factors 111, 113–14
  - patient-related factors 111, 112–13
  - travel medicine and tropical diseases 151
  - tuberculous infections 126–8
  - viral infections 114, 130–1
- antimigraine drugs 88–9
- antimitotic agents 182
- anti-oestrogens 176
- antiplatelet drugs 67–70
- anti-progestogen 174
- antipsychotics 97, 98–100, 104
- antiretrovirals 132–42
  - combination therapy using HAART 132, 135, 140–2
  - drug classes and drugs used in treatment 133–42
  - fusion and entry inhibitors 133–4, 139
  - integrase inhibitors 133–4, 140
  - mechanisms of drug action 132–3
  - non-nucleoside reverse transcriptase inhibitors 133–5, 138–9
  - nucleoside/nucleotide reverse transcriptase inhibitors 133–8
  - protease inhibitors 133–5, 138–9
  - special situations 141
- antithyroid drugs 256
- antituberculous drugs 126–8
- antivirals 114, 130–1
- anxiolytics 104–6
- apixaban 223
- aplastic anaemia 226
- apomorphine 94
- APTT *see* activated partial thromboplastin time
- ARB *see* angiotensin receptor blockers
- arrhythmias 274
- artemesinin 150, 152
- arterial disease 171
- AS *see* ankylosing spondylitis
- aspirin
  - blood conditions 225
  - cardiovascular disease 67–70

aspirin (*continued*)  
 gastrointestinal disease 28  
 inflammatory joint disease 198  
 mechanism of drug action 4  
 neurological disease 89  
 pregnancy 256  
 asthma 71–8  
 drugs used in treatment 72–8  
 features and characterisation 71  
 management of acute asthma 71  
 management principles 71–2  
 pregnancy 257–8  
 atacept 212  
 atenolol 31  
 atherosclerosis 52  
 atociban 175  
 atovaquone 149  
 atracurium 237  
 atrial myocardium 35  
 atrioventricular (AV) nodes 35, 37, 39–42  
 atypical antipsychotics 97, 99  
 AUR *see* acute urinary retention  
 autoimmune haemolytic anaemia 227  
 AV *see* atrioventricular  
 AVPU scale 271  
 azathioprine 27, 206

## B

$\beta$ -lactamases 114  
 $\beta$ -receptor blockers  
 coronary artery disease 31, 33, 38, 40, 46, 48, 50  
 endocrine disease 161–2  
 hypertension 56, 61–3  
 neurological disease 88  
 pregnancy 259  
 psychiatric disorders 106  
 $\beta_2$ -adrenoceptor agonists 72–3, 79, 175, 214  
 Bacille Calmette–Guérin (BCG) 214  
 bacterial infections 113–15, 117–26  
 bacterial meningitis 90  
 barbiturates 236  
 beclometasone 210  
 beclomethasone 74  
 belimumab 212  
 benign intracranial hypertension 116  
 benign prostatic enlargement (BPE) 178, 179  
 benzatropine 94  
 benzbromarone 203  
 benzodiazepines  
 pregnancy 256  
 psychiatric disorders 97, 105–7, 109  
 toxicology 278  
 benzyloquinoliniums 237  
 betamethasone 210  
 bezafibrate 66–7  
 biguanides 156  
 bile acid sequestrant resins 67

bioavailability 5–6  
 biological therapies  
 immunopharmacology 204, 205, 211–14  
 inflammatory joint disease 202  
 malignancies 191–4  
 bipolar disorder 103–4  
 bisoprolol 31, 46  
 bisphosphonates 164–5  
 bladder outlet obstruction (BOO) 178–80  
 bladder overactivity 179–80  
 bladder symptoms 92  
 bleomycin 189  
 blood conditions 215–27  
 activation of coagulation cascade 215–16  
 anaemia and haematinics 223–7  
 anticoagulants 217–23  
 drug-induced disorders 225–6  
 fibrinolysis 215–17  
 haemorrhage 222  
 immune mechanisms 226–7  
 pathophysiology 216–17  
 primary haemostasis 215  
 reversal of oral anticoagulation 222  
 thrombolytic agents 223  
 BMD *see* bone mineral density  
 bone marrow 116, 190, 226  
 bone metabolism 117, 163–7, 208  
 bone mineral density (BMD) 171  
 BOO *see* bladder outlet obstruction  
*Borrelia burgdorferi* 90  
 Botox 180  
 BPE *see* benign prostatic enlargement  
 bradycardia 62, 274  
 brand-name drugs 288  
 breast cancer 176, 195–6  
 breastfeeding 171–2, 260–1  
 bromocriptine 167–8  
 bronchiectasis 78–9  
 bronchodilators 72–5  
 bronchospasm 62  
 budesonide 26, 74  
 bupivacaine 234, 235  
 bupropion 77–8  
 buspirone 106

## C

C-reactive protein (CRP) 197  
 cabergoline 167–8  
 CABG *see* coronary artery bypass graft  
 calcitonin 166–7  
 calcium channel blockers  
 coronary artery disease 31–4, 40  
 hypertension 56, 57–9  
 pregnancy 259  
 reproductive system 175  
 calcium salts 163–4  
 cAMP *see* cyclic adenosine monophosphate

- cancer *see* malignancies
- candesartan 60–1
- cannabinoids 24
- capecitabine 188
- carbamazepine 82–3, 85, 104, 258
- carbapenems 119
- carbimazole 160–1
- carbohydrate metabolism 208
- carboplatin 187, 189
- cardiac arrest 284
- cardiac arrhythmia 34–42
  - classification of drug action 35–6
  - drugs used in treatment 37–42
  - mechanisms 35
  - non-pharmacological therapy 36
  - normal electrophysiology 35
- cardiac resynchronization therapy 51
- cardiogenic shock 50
- cardiovascular disease (CVD) 52–70
  - antiplatelet drugs 67–70
  - antiretrovirals 136
  - cholesterol and lipids 52–3, 57, 62, 64–7
  - hypertension 52–64
  - reproductive system 174
  - thrombosis 67–70
- carvedilol 31, 46
- casprofungin 130
- cataracts 209
- catechol-O-methyltransferase (COMT) inhibitors 94–5
- catheter radio-frequency ablation 36
- CBA *see* cost-benefit analysis
- CEA *see* cost-effectiveness analysis
- cell-mediated hypersensitivity 205
- central nervous system (CNS) 91, 136
- cephalosporins 113, 115, 119–20, 257
- cerebral malaria 90
- cerebrovascular disease 89–90
- cervical modification 174–5
- CHD *see* coronary heart disease
- chemoprophylaxis 143, 148–52
- chemotherapy 4, 185–96
  - adjuvant chemotherapy 186, 195–6
  - breast cancer 195–6
  - drugs used in treatment 188–9
  - management principles 186–8
  - metastatic testicular cancer 194
  - pathophysiology 186
  - patient selection 186
- CHF *see* congestive heart failure
- chlorambucil 188, 206
- chlordiazepoxide 97, 104
- chloroquine 149
- chlorphenamine 283–4
- chlorpromazine 23, 99, 104
- CHM *see* Commission on Human Medicines
- cholesterol 33, 52–3, 57, 62, 64–7
- chronic heart failure 50–1
- chronic myeloid leukaemia (CML) 192, 213
- chronic neurological disease 92
- chronic obstructive pulmonary disease (COPD) 31, 71–8
  - drugs used in treatment 72–8
  - features and characterisation 71
  - management of acute COPD 77
  - management principles 71–2
  - pharmacokinetics 9
- chronic oxygen therapy 78
- ciclosporin 27, 206–7, 211
- ciprofloxacin 117, 124
- citalopram 25
- clarithromycin 23, 117
- clearance 6–7, 113, 242–3
- clindamycin 123
- clinical trials 12–15
- clodronate 165
- clonazepam 83
- clonidine 63, 174
- clopidogrel 69–70, 89
- Clostridium botulinum* 180
- C. difficile* 28, 112, 115, 117, 122
- clotrimazole 129
- clotting factors 250
- cloxacillin 119
- clozapine 97, 99
- CMA *see* cost-minimisation analysis
- CML *see* chronic myeloid leukaemia
- CNS *see* central nervous system
- coagulation cascade 215–16
- co-amoxiclav 119
- COC *see* combined oral contraceptive
- cocaine 234, 235, 281
- codeine 25, 232
- colchicine 202
- coma 286
- combination therapy
  - antimicrobial therapy 114, 119, 121–2, 125
  - antiretrovirals 132, 135, 140–2
  - gastrointestinal disease 23
  - hormonal contraception 172–3
  - immunopharmacology 204, 211
  - neurological disease 89–90
  - pregnancy 258
- combinatorial chemistry 12
- combined oral contraceptive (COC) pill 169–72
- Commission on Human Medicines (CHM) 15
- community acquired candidiasis 114
- compliance 292
- COMT *see* catechol-O-methyltransferase
- concentration–effect relationships 3, 5
- concordance 292
- congestive heart failure (CHF) 47
- connective tissue disease 260
- constipation 25–6
- continuous positive airway pressure (CPAP) 50
- contraception 169–73, 176
- conventional antipsychotics 98–9
- convulsions 116
- convulsive status epilepticus 82
- COPD *see* chronic obstructive pulmonary disease

- coronary angiography 34
  - coronary artery bypass graft (CABG) 34
  - coronary artery disease 29–51
    - acute coronary syndromes 29–34
    - angina pectoris 29–34
    - cardiac arrhythmia 34–42
    - heart failure 42–51
  - coronary heart disease (CHD) 52–3
  - corticosteroids
    - chemotherapy 189
    - gastrointestinal disease 26, 209
    - immunopharmacology 207–11
    - inflammatory joint disease 200, 202
    - respiratory disease 73–4, 79
  - cortisol 208–10
  - Corynebacterium parvum* 214
  - cost-benefit analysis (CBA) 264
  - cost-effectiveness analysis (CEA) 264, 266–7
  - cost-minimisation analysis (CMA) 264
  - cost-utility analysis (CUA) 262, 264–5
  - co-trimoxazole 121–2
  - coughing 60
  - covert poisoning 269
  - COX-2 *see* cyclooxygenase
  - CPAP *see* continuous positive airway pressure
  - cranial diabetes insipidus 167
  - creatinine clearance 6–7, 113, 242–3
  - Crohn's disease 26–7
  - CRP *see* C-reactive protein
  - CUA *see* cost-utility analysis
  - CVD *see* cardiovascular disease
  - cyclic adenosine monophosphate (cAMP) 214
  - cyclooxygenase (COX-2) inhibitors 175, 198–200, 202, 230
  - cyclophosphamide 187–8, 190, 195, 206
  - cyproterone acetate 177
  - Cys leukotriene receptor antagonists 74–5
  - cystic fibrosis 79
  - cytochrome P450
    - coronary artery disease 33
    - drug development 13
    - hepatic disease 250
    - pharmacokinetics 8–10
  - cytotoxic agents *see* chemotherapy
- D**
- DA *see* dopamine agonists
  - dagibatran 222–3
  - danazol 176
  - dapsone 149
  - daptomycin 125–6
  - darbepoetin alfa 225
  - daunorubicin 189
  - DC cardioversion 36
  - DDP-4 *see* dipeptidyl peptidase 4
  - decarbazine 189
  - deep venous thrombosis (DVT) 215, 217–20
  - delayed-type hypersensitivity (DTH) 205
  - dementia 97, 110
  - denosumab 165
  - dental staining 117
  - dependence 256
  - depot antipsychotics 99–100
  - depression
    - neurological disease 92
    - pregnancy 259–60
    - psychiatric disorders 97, 100–3
  - deranged brain function 250
  - dexamethasone 191, 210
  - diabetes mellitus 153–9
    - aims of treatment 153–4
    - antiretrovirals 136
    - drugs used in treatment 154
    - hyperosmolar hyperglycaemic state 159
    - hypoglycaemic coma 159
    - insulin therapy 153, 154–6, 158–9
    - ketoacidosis 158–9
    - non-pharmacological therapy 154
    - oral hypoglycaemic agents 156–8
    - pathophysiology 153
    - pharmacodynamics and pharmacokinetics 3
    - pregnancy 257
  - diabetic emergencies in adults 158
  - diabetic ketoacidosis (DKA) 158–9
  - diamorphine 49, 232
  - diarrhoea 24–5
  - diazepam 256–7, 286
  - diclofenac 199
  - dietary factors 65, 154, 163
  - digoxin
    - coronary artery disease 39–42, 48, 50
    - dosage individualisation 242, 243–4
    - toxicology 281
  - digoxin-induced toxicity 42, 48
  - dihydropyridines 31–2, 33, 40, 56, 58–9
  - diltiazem 31–2, 34, 40, 58–9
  - dipeptidyl peptidase 4 (DDP-4) inhibitors 158
  - diphenoxylate 25
  - dipyridamole 69–70
  - direct costs 263
  - discontinuation of treatment 290
  - disease-modifying antirheumatic drugs (DMARD) 197–8, 200–1, 204
  - disinhibition 97
  - disodium cromoglicate 214
  - disopyramide 37
  - distribution
    - analgesia 232
    - antimicrobial therapy 115, 118
    - drug interactions 291–2
    - elderly patients 253
    - pharmacokinetics 6
    - pregnancy 256
  - disulfiram 109
  - diuretics
    - coronary artery disease 44–5
    - emergency treatments 285

hypertension 55–7  
 neurological disease 89  
 DKA *see* diabetic ketoacidosis  
 DMARD *see* disease-modifying antirheumatic drugs  
 dobutamine 48  
 docetaxel 182, 195  
 domperidone 20–1, 24  
 donepezil 110  
 dopamine 48  
 dopamine agonists (DA) 94–5, 167–8  
 dopamine antagonists 20–1, 23–4  
 dopaminergic side effects 94  
 dosage forms 6–8  
 dosage individualisation 241–6  
   clearance estimates 242–3  
   interpretation of serum concentrations 243  
   therapeutic drug monitoring 241–2, 243–6  
 dose ranging studies 13  
 dose–response relationships 3, 5  
 doxazosin 63  
 doxorubicin 189  
 doxycycline 149, 152  
 dronedarone 39  
 drug development 11–15  
   clinical trials 12–15  
   pharmacodynamics and pharmacokinetics 3–4, 12  
   pharmacovigilance 14–15  
   translational research 15  
   UK and European regulation context 11–12  
   Yellow Card scheme 15  
 drug-induced disorders  
   blood conditions 225–6  
   coronary artery disease 34, 36, 42, 48  
   gastrointestinal disease 27–8  
   hepatic disease 250–1  
   hypertension 54  
   neurological disease 85, 90–1  
   psychiatric disorders 108  
 drug interactions  
   analgesia 232  
   antimicrobial therapy 115, 118–30  
   antiretrovirals 135, 138–9  
   blood conditions 221  
   chemotherapy 190–1  
   coronary artery disease 32, 39–42, 44–6  
   dosage individualisation 241  
   elderly patients 254  
   gastrointestinal disease 20, 22, 24  
   hormonal contraception 172, 176  
   immunopharmacology 207  
   inflammatory joint disease 203  
   pharmacokinetics 9–10  
   prescribing practice 291–2  
   psychiatric disorders 104, 105  
   respiratory disease 72–5  
 drug resistance  
   antimicrobials 112, 114, 115  
   antiretrovirals 135, 138–9  
   travel medicine and tropical diseases 152

drug sensitivity 113  
 DTH *see* delayed-type hypersensitivity  
 DU *see* duodenal ulcers  
 DUB *see* dysfunctional uterine bleeding  
 duodenal ulcers (DU) 20, 22  
 DVT *see* deep venous thrombosis  
 dysfunctional uterine bleeding (DUB) 174  
 dyslipidaemias 57, 64–5, 135–6, 138  
 dystonic reactions 274

## E

echinocandins 130  
 economic evaluations 262–8  
   cost-benefit analysis 264  
   cost-effectiveness analysis 264, 266–7  
   cost-minimisation analysis 264  
   cost-utility analysis 262, 264–5  
   costs 263–4  
   decision-making 262–3, 267–8  
   perspective 263  
   resource scarcity 262  
   sensitivity analysis 267  
 ecstasy (MDMA) 281  
 efalizumab 212  
 efficacy testing 12  
 elderly patients 253–4  
 electrolyte balance 208  
 elimination  
   antimicrobial therapy 115, 118  
   elderly patients 254  
   hepatic disease 249–50  
   pharmacokinetics 7–10  
   pregnancy 256–7  
   renal disease 247–8  
 elimination half-life 7–8  
 EMEA *see* European Medicines  
   Evaluation Authority  
 emergency contraception 172  
 emergency treatments 283–6  
   acute left ventricular failure 285  
   anaphylaxis 283–4  
   cardiac arrest 284  
   hypoglycaemic coma 286  
   opioid poisoning 286  
   status epilepticus 285–6  
   supraventricular tachycardia 284–5  
 EMLA *see* eutectic mixture of local anaesthetics  
 endocrine disease 153–68  
   bone metabolism 163–7  
   diabetes mellitus 3, 136, 153–9  
   hyperosmolar hyperglycaemic state 159  
   hypertension 54  
   hypoglycaemic coma 159  
   ketoacidosis 158–9  
   obesity 162–3  
   pituitary and adrenal cortex disease 167–8  
   thyroid disease 160–2

enhanced drug elimination 275  
 entacapone 94, 95  
 environmental poisoning 269  
 enzymes 4–5, 9–10  
 EPAR *see* European Public Assessment report  
 epilepsy 81–7  
   aetiology of seizures 81–2  
   drugs used in treatment 82–7  
   pathophysiology 81  
   pregnancy 86–7, 258  
 epinephrine 283, 284  
 epirubicin 189, 195  
 eplerenone 45, 47  
 epoetin 225  
 EPS *see* extrapyramidal side effects  
 eptifibatid 70  
 erectile dysfunction 182–4  
 ergotamine 88  
 erythrocyte sedimentation rate (ESR) 197  
 erythromycin 123  
 erythropoietin 225  
 esomeprazole 20  
 ESR *see* erythrocyte sedimentation rate  
 etanercept 212  
 ethambutol 126–7, 257  
 ethosuximide 83  
 etidronate 165  
 etodolac 199  
 etomidate 236  
 etoposide 187–8, 189  
 European Medicines Evaluation Authority (EMA) 11, 14–15  
 European Public Assessment report (EPAR) 14  
 eutectic mixture of local anaesthetics (EMLA) 235  
 excretion 232  
 exenatide 157  
 extrapyramidal side effects (EPS) 99–100  
 ezetimibe 67

## F

faecal bulk 25  
 famciclovir 130  
 familial hypercholesterolaemia 64  
 fampridine 92  
 fatigue 62, 92  
 FDA *see* Food and Drug Administration  
 febuxostat 202, 203  
 felodipine 31–2  
 fenamates 199  
 fentanyl 233  
 fertility 171, 176, 190  
 fibrates 66–7  
 fibrinolysis 215–17  
 fidaxomicin 126  
 first in man studies 13  
 first-pass metabolism 6, 249  
 fish oils 67

flecainide 37–8  
 flucloxacillin 117, 119  
 fluconazole 129  
 flucytosine 129  
 fluid balance 208–9  
 fluid overload 251  
 fluid replacement therapy 158–9  
 fluid retention 190, 209, 248  
 5-fluorouracil 195  
 fluoxetine 174  
 flupentixol 99–100  
 fluphenazine 99–100  
 fluticasone 74  
 fluvastatin 66  
 focal migraine 171  
 folic acid 224, 225  
 fondaparinux 219  
 Food and Drug Administration (FDA) 14  
 food interactions 135, 138–9  
 force of cardiac contraction 43  
 forced diuresis 275  
 formoterol 72  
 fosphenytoin 86  
 frusemide 115  
 fulvestrant 191  
 fumetanide 44–5  
 fungal infections 114, 128–30  
 furosemide 4, 44–5, 49  
 fusion and entry inhibitors 133–4, 139

## G

G-CSF *see* granulocyte-colony stimulating factor  
 gabapentin 83, 88  
 gastric lavage 273  
 gastric ulcers (GU) 20, 22  
 gastrointestinal bleeding 68–9, 70, 198–9  
 gastrointestinal decontamination 273  
 gastrointestinal disease 19–28  
   diarrhoea and constipation 24–6  
   drug-induced problems 27–8  
   gastro-oesophageal reflux disease 19–21, 22  
   immunopharmacology 209  
   inflammatory bowel disease 26–7  
   nausea and vomiting 23–4  
   peptic ulcers 21–3  
 gastro-oesophageal reflux disease (GORD) 19–21, 22  
 gemfibrozil 66–7  
 general anaesthesia 235–7  
 generalised epilepsy 82  
 generalised status epilepticus 82  
 generic drugs 288  
 genetic factors 10, 290  
 genomics 3  
 gentamicin 115, 117, 241, 244–5  
 GI *see* gastrointestinal  
 glatiramer acetate 92  
 gliclazide 156–7

glitazones 157  
glomerular filtration 10  
glucagon 286  
glucagon-like peptide 1 (GLP-1) agonists 157–8  
glucocorticoids 168, 191, 208–10  
glucuronidation 9  
glucose tolerance 171  
glucose-6-phosphate dehydrogenase 226  
glyceryl trinitrate (GTN) 30, 33, 49–50, 64  
glycopeptides 124  
glycoprotein IIb/IIIa receptor antagonists 70  
gold 201  
gonadotrophin-releasing hormone (GnRH) 176–7, 181–2  
Good Clinical Practice Guidelines 12  
GORD *see* gastro-oesophageal reflux disease  
goserelin 191  
gout 197, 202–3  
GPIIa/IIIa *see* platelet glycoprotein receptor  
granulocyte-colony stimulating factor (G-CSF) 225  
Graves' disease 160–2  
griseofulvin 130  
GTN *see* glyceryl trinitrate  
GU *see* gastric ulcers

## H

HAART *see* highly active antiretroviral therapy  
haematinics 223–5  
haematology *see* blood conditions  
haematopoietic growth factors 225  
haemodialysis 275–6  
haemolytic anaemia 116, 226–7  
haemoperfusion 276  
haemorrhage 222  
haemostasis 68, 215  
haloperidol 104  
HCG *see* human chorionic gonadotrophin  
HDL *see* high-density lipoprotein  
headache 87  
heart failure 42–51  
    definition 43  
    drugs used in treatment 43, 44–9  
    long-term management 50–1  
    management principles 43, 49–50  
    neuroendocrine activation 44  
*Helicobacter pylori* 20, 21–3  
helminthic infections 151, 152  
heparin 217–19, 259  
heparinoids 219  
hepatic function  
    antimicrobial therapy 113, 116  
    metabolism 248  
    pharmacokinetics 6, 249–51  
    toxicology 280–1  
hepatitis A 144  
hepatotoxicity 137, 250–1  
HER2 *see* human epidermal growth factor 2  
heroin 232  
herpes simplex encephalitis (HSE) 90  
HHS *see* hyperosmolar hyperglycaemic state  
high-density lipoprotein (HDL) cholesterol 57, 62, 65–7  
high extraction drugs 249  
highly active antiretroviral therapy (HAART) 132, 135, 140–2  
hirudins 219  
histamine H<sub>2</sub>-receptor antagonists 20, 21–2, 25  
His-Purkinje system 35  
HIV/AIDS 113, 132–42  
    antiretrovirals 132–42  
    combination therapy using HAART 132, 135, 140–2  
    drug classes and drugs used in treatment 133–42  
    fusion and entry inhibitors 133–4, 139  
    HIV-2 infection 141  
    immunopharmacology 213  
    integrase inhibitors 133–4, 140  
    mechanisms of drug action 132–3  
    non-nucleoside reverse transcriptase inhibitors 133–5, 138–41  
    nucleoside/nucleotide reverse transcriptase inhibitors 133–8, 140–1  
    protease inhibitors 133–5, 138–41  
    special situations 141  
    transmission 141  
    travel medicine and tropical diseases 143  
HMG CoA reductase inhibitors *see* statins  
HNIG *see* human normal pooled immunoglobulin  
homeostasis 254  
hormonal contraception 169–73, 176  
hormone therapy 191  
hormone-replacement therapy (HRT)  
    endocrine disease 165–6, 167  
    hormonal contraception 170  
    menopausal symptoms 173–4  
    urological system 183  
hot flushes 173–4, 177  
HRT *see* hormone-replacement therapy  
HSE *see* herpes simplex encephalitis  
human chorionic gonadotrophin (HCG) 185  
human epidermal growth factor 2 (HER2) gene 193–4  
human immunodeficiency virus *see* HIV/AIDS  
human normal pooled immunoglobulin (HNIG) 144  
hydralazine 47, 259  
hydrocortisone 210  
hydrolysis 8–9  
hydroxocobalamin 224  
hydroxycarbamide 189  
hydroxychloroquine 200, 206  
hyoscine 23  
hypercalcaemia 57, 165, 167  
hypercholesterolaemia 9  
    cardiovascular disease 52–3, 64–7  
    coronary artery disease 29  
hyperglycaemia 57, 153, 156–8  
hyperkalaemia 274  
hyperlipidaemia 57, 136, 138  
hyperosmolar hyperglycaemic state (HHS) 159  
hyperreflexia 274–5



- hypersensitivity reactions
    - antimicrobial therapy 115, 117, 118, 120
    - antiretrovirals 137
    - blood conditions 219
    - chemotherapy 190
    - immunopharmacology 205
  - hypertension 52–64
    - benefits of treatment 54–5
    - coronary artery disease 29
    - drugs used in treatment 55–64
    - management principles 54–5
    - neurological disease 91
    - pregnancy 259
    - primary and secondary 54
    - reproductive system 171
    - respiratory disease 79–80
    - toxicology 274
  - hypertensive emergencies 63–4
  - hyperthermia 274
  - hyperthyroidism 160–2, 259
  - hypertonia 274–5
  - hyperuricaemia 57, 190
  - hypnotics 106–7, 235
  - hypoglycaemia 62, 156
  - hypoglycaemic coma 159, 286
  - hypokalaemia
    - coronary artery disease 45
    - hypertension 55, 57
    - toxicology 273
  - hypoptuitarism 167
  - hyporeflexia 274
  - hypotension 59, 274
  - hypothermia 274
  - hypothyroidism 162
  - hypotonia 274
- I**
- ibandronate 165
  - IBS *see* irritable bowel syndrome
  - ibuprofen 199
  - ICER *see* incremental cost effectiveness ratio
  - ICH *see* International Conference on Harmonization
  - idiopathic interstitial pneumonia 79
  - idiosyncratic drug reactions 290–1
  - idoxuridine 130–1
  - imatinib mesylate 192–3, 213
  - imidazoles 129
  - immediate hypersensitivity 205
  - immune complex-mediated hypersensitivity 205
  - immune haemolytic anaemia 226–7
  - immunisation 143–7
  - immunomodulatory agents 213
  - immunopharmacology 204–14
    - acquired or adaptive immunity 204–5
    - biological therapies 204, 205, 211–14
    - clinical use and dosage of steroids 210–11
    - combination therapy 204, 211
    - corticosteroids 207–11
    - hypersensitivity reactions 205
    - immune response suppression 205
    - immune system acting drugs 214
    - immunostimulatory and immunomodulatory agents 213–14
      - innate or natural immunity 204
      - small chemical agents 205–6
      - T-cell targeting agents 206–7
      - tyrosine kinase inhibitors 213
    - immunostimulatory agents 213–14
    - immunosuppression
      - antimicrobial therapy 113
      - gastrointestinal disease 27
      - respiratory disease 79
    - impotence 57, 92
    - in vitro* studies 12
    - incremental cost effectiveness ratio (ICER) 266–7
    - indirect costs 263
    - indomethacin 175, 199, 256
    - induced vomiting 273
    - induction 9
    - infections
      - antimicrobial therapy 111–31
      - antiretrovirals 132–42
      - neurological disease 90
      - pregnancy 257
      - tropical diseases 143–52
      - see also* HIV/AIDS
    - inflammatory bowel disease 26–7
    - inflammatory joint disease 197–203
      - biological therapies 202
      - gout and pseudogout 197, 202–3
      - management principles 197–8
      - symptom modification 198–202
    - inflammatory responses 208
    - infliximab 27, 212
    - inhalation anaesthesia 236–7
    - inhaled corticosteroids 73–4
    - inhibition 9–10
    - innate immunity 204
    - INR *see* international normalised ratio
    - insomnia 106–7
    - insulin resistance 136, 138
    - insulin therapy 153, 154–6, 158–9
    - intangible costs 263
    - integrase inhibitors 133–4, 140
    - intentional self-poisoning 269
    - interaction studies 13
    - intercranial haemorrhage 89
    - interferons 92, 131, 213
    - interleukins 204–5, 206–7, 213
    - International Conference on Harmonization (ICH) 12
    - international normalised ratio (INR) 220–2
    - interstitial lung disease 79
    - intracranial hypertension 91
    - intrauterine system (IUS) 169–72, 174
    - intravenous administration 6–8, 235–6
    - intravenous human immunoglobulin (IVIg) 91–2

ipratropium bromide 73  
 irbesartan 60–1  
 irinotecan 189  
 iron deficiency anaemia 224  
 iron toxicity 281–2  
 irritable bowel syndrome (IBS) 24–5  
 ischaemic stroke 89–90, 171  
 isoniazid 126–8, 257  
 isosorbide dinitrate/mononitrate 30–1, 47, 49  
 itraconazole 129  
 IUS *see* intrauterine system  
 ivabradine 32–3, 47–8, 50  
 IVIg *see* intravenous human immunoglobulin

## K

Kaposi's sarcoma 213  
 ketamine 236  
 ketoacidosis 158–9  
 ketoconazole 129  
 ketotifen 214  
 kidney function *see* renal function

## L

LABA *see* long-acting  $\beta_2$ -agonists  
 lactic acidosis 135–6  
 lamotrigine 83, 86, 258  
 lansoprazole 20  
 laxatives 25–6  
 LDL *see* low-density lipoprotein  
 lead toxicity 282  
 leflunomide 201, 207  
 leukaemias 186, 187  
 leuprorelin 191  
 levamisole 214  
 levetiracetam 83, 86  
 levobupivacaine 235  
 levodopa 93, 94–5  
 levofloxacin 124–5  
 levonorgestrel (LNG) 170–4  
 levosimendan 49  
 levothyroxine sodium 162  
 LHRH *see* luteinising-hormone releasing hormone  
 lidocaine 37, 234, 235  
 lifestyle factors 65, 154, 163  
 linagliptin 158  
 linear kinetics 8  
 linezolid 125  
 liothyronine sodium 162  
 lipid metabolism 171, 208  
 liraglutide 157  
 lithium 271, 281  
 lithium carbonate 103–4  
 live vaccines 146–7  
 liver function *see* hepatic function  
 LNG *see* levonorgestrel

loading doses 6  
 local anaesthesia 233–5  
 long-acting  $\beta_2$ -agonists (LABA) 72–3, 79  
 long-term oxygen therapy (LTOT) 78, 80  
 loop diuretics 44–5, 56, 285  
 loperamide 25  
 lorazepam 285–6  
 losartan 60–1  
 low-density lipoprotein (LDL) cholesterol 33, 57, 64–7  
 low-dose aspirin 68  
 low extraction drugs 249–50  
 low molecular weight heparin 217, 218  
 lower urinary tract symptoms (LUTS) 178–9  
 LTOT *see* long-term oxygen therapy  
 luteinising-hormone releasing hormone (LHRH) 181–2  
 LUTS *see* lower urinary tract symptoms  
 Lyme disease 90  
 lymphomas 186, 187

## M

macrolides 123  
 magnesium sulphate 76  
 maintenance dose 243  
 major histocompatibility complex (MHC) 204–5  
 malaria 114, 147–52  
 malarone 148  
 malignancies 185–96  
   adjuvant chemotherapy 186, 195–6  
   biological therapies 191–4  
   breast cancer 195–6  
   chemotherapy 185–96  
   drugs used in treatment 188–9  
   endocrine disease 167–8  
   immunopharmacology 213  
   management principles 186–8  
   metastatic testicular cancer 194  
   pathophysiology 186  
   patient selection 186  
   prescribing practice 290–1  
   reproductive system 171, 174, 176  
   urological system 181–2, 183  
 malignant teratoma undifferentiated (MTU) 185  
 MAOI *see* monoamine oxidase inhibitors  
 marginal costs 263  
 MDAC *see* multiple dose activated charcoal  
 MDMA (ecstasy) 281  
 mebeverine 25  
 Medicines and Healthcare products Regulatory Agency (MHRA) 11, 15  
 mefloquine 114, 148, 149  
 megaloblastic anaemia 224, 225  
 melatonin 107  
 meloxicam 199  
 melphalan 187–8  
 membrane ionic channels 4  
 menopausal symptoms 173–4, 176–7  
 menstruation 171

mercaptoethone sulphonate 190  
 6-mercaptopurine 27, 191  
 metabolic acidosis 273  
 metabolism  
   analgesia 232  
   antiretrovirals 136, 138  
   drug interactions 291–2  
   elderly patients 254  
   genetic factors 10  
   hepatic disease 249  
   hypertension 62  
   immunopharmacology 208–9  
   pharmacokinetics 8–10  
   renal disease 248  
 metastatic bone disease 165, 167  
 metastatic cancer 187, 194  
 metformin 156, 176  
 methadone 232  
 methimazole 160–1  
 methotrexate 27, 187–8, 191, 201, 206, 211  
 methyl dopa 63, 259  
 methylmorphine 232  
 methylprednisolone 91, 92  
 methysergide 88  
 methicillin-resistant *Staphylococcus aureus* (MRSA) 112, 115  
 metoclopramide 20–1, 24  
 metoprolol 46  
 metronidazole 23, 122–3  
 mexiletine 37  
 MHC *see* major histocompatibility complex  
 MHRA *see* Medicines and Healthcare products Regulatory Agency  
 MI *see* myocardial infarction  
 miconazole 129  
 mifepristone 174  
 migraine 87–9, 171  
 mineralocorticoids 168, 208, 210–11  
 mirtazepine 103  
 mitosis inhibitors 188–9  
 mitoxantrone 92–3  
 monoamine oxidase inhibitors (MAOI)  
   neurological disease 85, 94–5  
   psychiatric disorders 101, 102, 106  
   toxicology 278  
 monoclonal antibodies 76, 165  
 montelukast 74–5  
 mood stabilisers 103–4  
 morphine 49, 231–2, 285  
 movement disorders 93–6  
 moxifloxacin 125  
 MRSA *see* methicillin-resistant *Staphylococcus aureus*  
 MS *see* multiple sclerosis  
 MTU *see* malignant teratoma undifferentiated  
 mucolytics 76  
 multiple dose activated charcoal (MDAC) 282  
 multiple sclerosis (MS) 91–2  
 muscle spasms 92  
 mushroom toxicity 282  
 myasthenia 90

*Mycobacterium tuberculosis* 126–8  
 mycophenolate mofetil 206  
 myocardial compliance 43  
 myocardial contractility 62  
 myocardial infarction (MI) 29–30, 34, 171, 223  
 myopathy 90

## N

N&V *see* nausea and vomiting  
 N-methyl-D-aspartic acid (NMDA) antagonists  
   94, 95–6  
 nabilone 24  
 nabumetone 199  
 naloxone 233, 286  
 naproxen 199  
 National Poisons Information Service (NPIS) 270  
 natulizumab 93  
 natural immunity 204  
 nausea and vomiting (N&V)  
   chemotherapy 190  
   gastrointestinal disease 23–4  
   neurological disease 87  
   pregnancy 257  
 nephrotoxicity 137  
 nesiritide 49  
 neuroendocrine activation 44  
 neuroendocrine antagonists 45–8  
 neuroimmunology 91–3  
 neurological disease 81–96  
   cerebrovascular disease 89–90  
   drug-induced disorders 85, 90–1  
   epilepsy 81–7  
   headache 87  
   immunopharmacology 209  
   infections of the nervous system 90  
   migraine 87–9  
   movement disorders 93–6  
   neuroimmunology 91–3  
 neurological eighth nerve 116  
 neuromuscular-blocking drugs 116, 237  
 neurons 228  
 neuropathy 190, 229  
 neutropenia 116, 137, 227  
 nicotine replacement therapy 77  
 nicotinic acid derivatives 67  
 nifedipine 4, 31–2, 58, 175, 259  
 nimodipine 89  
 nitrofurantoin 123–4  
 nitrous oxide 236  
 NIV *see* non-invasive ventilation  
 NMDA *see* N-methyl-D-aspartic acid  
 NNRTI *see* non-nucleoside reverse transcriptase inhibitors  
 non-depolarising muscle relaxants 237  
 non-dihydropyridines 31–2, 56, 58–9  
 non-invasive ventilation (NIV) 50  
 non-linear kinetics 8

non-nucleoside reverse transcriptase inhibitors (NNRTI)  
133–5, 138–41

non-opioid analgesics 229, 230

non-ST segment elevation myocardial infarction (non-STEMI) 30, 34

non-steroidal anti-inflammatory drugs (NSAID)

- analgesia 230
- coronary artery disease 45
- gastrointestinal disease 19–21, 28
- inflammatory joint disease 197–200, 202
- neurological disease 87–8
- toxicology 278

NPIS *see* National Poisons Information Service

nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) 133–8, 140–1

nystatin 129

## O

OA *see* osteoarthritis

OAB *see* overactive bladder

obesity 162–3

occupational poisoning 269

oestrogens 182, 191

omeprazole 20

ondansetron 24

opiates 109–10

opioid partial agonists 231, 233

opioid receptor agonists 231–3

opioid receptor antagonists 231, 233

opioids

- analgesia 229, 230–3
- emergency treatments 286
- pregnancy 256
- toxicology 278, 281, 286

opportunity costs 263

optic nerve disorders 116

optic neuropathy 90

oral administration

- anticoagulants 219–23
- hypoglycaemic agents 156–8
- pharmacokinetics 6–7

oral-activated charcoal 273, 276, 282

organogenesis 255–6

orlistat 163

oseltamavir 131

osmotic laxatives 26

osteoarthritis (OA) 197

osteopenia 137

osteoporosis 137, 164–7, 209, 219

overactive bladder (OAB) 179–80

overdose 269, 276–82

- analgesics 278–81
- antidepressants 276–8
- inflammatory joint disease 199
- other substances 281–2
- substance abuse 281

ovulation-induction 176–7

oxicams 199

oxycodone 232–3

oxygen therapy 78

oxytocin 174–5

## P

paclitaxel 182

paediatric patients 141, 252–3

Paget's disease 165, 166

pain

- adjuvant pain relief 229, 233
- anaesthesia 228, 233–7
- analgesia 228–33
- inflammatory joint disease 197–8
- neurological disease 92
- non-opioid analgesics 229, 230
- opioids 229, 230–3
- pathophysiology 228
- principles of analgesia 229
- WHO analgesic ladder 229

pamidronate 165

pancreatic disease 153

pancreatic insufficiency 25

pancreatic lipase inhibitors 163

pancreatitis 137, 158

pantoprazole 20

paracetamol 87, 230, 279–81

paranoid schizophrenia 97

parasitic infections 151, 152

parenteral anticoagulants 217–19

parenteral iron 224

parkinsonism 90, 94–6, 99–100

Parkinson's disease (PD) 93–6

paroxetine 174

partial agonists 4–5

partial epilepsy 81

passive immunisation 144

passive reabsorption 10

PCI *see* percutaneous coronary intervention

PCOS *see* polycystic ovarian syndrome

PD *see* Parkinson's disease

PDE<sub>4</sub> *see* phosphodiesterase 4 inhibitors

penicillinase-resistance 119

penicillinase-sensitivity 119

penicillins 113, 115, 117–19, 257

peptic ulcers (PU) 21–3

percutaneous coronary intervention (PCI) 30, 34

peripheral nervous system (PNS) 91

peripheral neuropathy 90, 116, 137

peripheral vasoconstriction 62

pethidine 233

pharmacodynamics 3–5

- antimicrobial therapy 111
- definition and characteristics 3
- dose–response relationships 3, 5
- drug interactions 291

- pharmacodynamics (*continued*)
  - mechanism of drug action 4–5
  - paediatric patients 252
  - principles of drug action 4
- pharmacoeconomics 262–8
  - cost-benefit analysis 264
  - cost-effectiveness analysis 264, 266–7
  - cost-minimisation analysis 264
  - cost-utility analysis 262, 264–5
  - costs 263–4
  - decision-making 262–3, 267–8
  - perspective 263
  - quality adjusted life years 262, 264–7
  - resource scarcity 262
  - sensitivity analysis 267
- pharmacokinetics 3–4, 5–10
  - absorption 5–6
  - analgesia 232
  - antimicrobial therapy 111, 115, 118, 120, 122, 124–30
  - antiretrovirals 135, 138
  - cardiovascular disease 68
  - chemotherapy 189
  - clearance 6–7
  - clinical trials 13–14
  - coronary artery disease 30–1, 33, 37–8, 40–2, 44, 48
  - definition and characteristics 3
  - distribution 6
  - dosage individualisation 241–6
  - dose–response relationships 3
  - drug interactions 9–10, 291–2
  - efficacy and toxicity testing 12
  - elderly patients 253–4
  - elimination 7–10
  - endocrine disease 155–8, 161–4, 166–7
  - gastrointestinal disease 19–22
  - genetic factors 10
  - hepatic disease 249–51
  - immunopharmacology 206–7
  - inflammatory joint disease 198, 203
  - linear versus non-linear kinetics 8
  - metabolism 8–10
  - neurological disease 82–6, 88
  - paediatric patients 252
  - pregnancy 256–7
  - psychiatric disorders 99, 101–3, 105
  - renal disease 247–9
  - renal excretion 10
  - reproductive system 170, 175
  - respiratory disease 72–5
  - single intravenous bolus doses 7–8
  - toxicology 275
- pharmacovigilance 14–15
- phase I clinical trials 12–13
- phase II clinical trials 13–14
- phase III clinical trials 14
- phase IIIb and IV studies 14–15
- phenothiazines 23
- phenylacetic acid derivatives 199
- phenytoin
  - coronary artery disease 37
  - dosage individualisation 245–6
  - neurological disease 85
  - pharmacokinetics 6
  - pregnancy 256–7, 258
- phosphodiesterase 4 (PDE<sub>4</sub>) inhibitors 75, 182–3
- photophobia 87
- physiological support systems 276
- PI *see* protease inhibitors
- pioglitazone 157
- piperacillin-tazobactam 119
- piroxicam 199
- pituitary disease 167–8
- pizotifen 88
- plasma protein binding 6
- Plasmodium* spp. 147–52
- platelet glycoprotein receptor (GPIIb/IIIa) antagonists 34
- PNS *see* peripheral nervous system
- poisoning 269–76
  - antidotes 277
  - assessment and diagnosis 270–2
  - emergency treatments 286
  - enhanced drug elimination 275
  - general approach to poisoned patient 270–4
  - haemodialysis 275–6
  - haemoperfusion 276
  - immediate management 273–4
  - management of specific complications 274–5
  - pharmacokinetics 275
  - physiological support systems 276
  - specific treatments 275
  - toxicological analyses 272–3
- polycystic ovarian syndrome (PCOS) 176
- polygenic dyslipidaemias 64
- polypharmacy 254
- polysaccharides 25
- POP *see* progesterone-only pill
- potassium channel activators 32
- potassium iodide 161
- potassium replacement therapy 159
- potassium-sparing diuretics 45, 56
- PPI *see* proton pump inhibitors
- PR intervals 37, 41
- pramipexole 94
- prasugrel 69
- pravastatin 66
- prazosin 63
- preclinical studies 12
- prednisolone 76–7, 189, 202, 210
- pregabalin 84
- pregnancy 255–60
  - antiretrovirals 141
  - blood conditions 220, 222
  - chemotherapy 190
  - common medical problems 257–60
  - drugs given at end of pregnancy 256
  - drugs used in treatment 257–60
  - epilepsy 86–7

fertilisation and implantation period 255  
 fetal effects of drugs 255–6  
 growth and development period 256  
 organogenesis 255–6  
 pharmacokinetics 256–7  
 prescribing practice 290  
 reproductive system 174–5  
 preload 43, 49  
 prescribing practice 287–93  
 administrative route 287–8  
 adverse drug reactions 289  
 best practice 288–9  
 compliance, concordance and adherence 292–3  
 dosage and dosage intervals 288  
 drug interactions 291–2  
 drug selection 287  
 generic and brand-name drugs 288  
 genetic factors 290  
 idiosyncratic drug reactions 290–1  
 key questions before prescribing 287–8  
 minimising harm to patients 292–3  
 mistakes and outcomes 289  
 need for drug treatment 287  
 practicalities 288  
 withdrawal and rebound symptoms 290  
 priapism 184  
 prilocaine 234, 235  
 primaquine 150, 152  
 primary dyslipidaemias 64  
 primary haemostasis 215  
 primary hypertension 54  
 pristinamycin 125  
 probenecid 203  
 procainamide 37  
 procaine 234  
 procarbazine 189, 191  
 prochlorperazine 23  
 progesterone therapy 191  
 progesterone-only pill (POP) 169–73  
 proguanil 149, 152  
 promethazine 23  
 propafenone 38  
 propanolol 88  
 propionic acid derivatives 199  
 propofol 236  
 propranolol 106, 161–2  
 propylthiouracil 160–1, 259  
 prostaglandins 175, 184  
 prostate cancer 181–2  
 protease inhibitors (PI) 133–5, 138–41  
 protein binding 248, 249–50  
 protein metabolism 208  
 proteomics 3  
 prothrombin time 280–1  
 proton pump inhibitors (PPI) 20, 22, 25  
 protozoan infections 114  
 prucalopride 26  
 PsA *see* psoriatic arthritis  
 pseudogout 197, 202–3

psoriatic arthritis (PsA) 197  
 psychiatric disorders 97–110  
 abuse of psychoactive drugs 108–10  
 antidepressants 97, 100–3  
 antipsychotics 97, 98–100, 104  
 anxiolytics 104–6  
 dementia 97, 110  
 drug-induced psychiatric disorder 108  
 hypnotic drugs 106–7  
 insomnia 106–7  
 mood stabilisers 103–4  
 psychosis 209  
 PU *see* peptic ulcers  
 pulmonary fibrosis 117  
 pulmonary hypertension 79–80  
 pyrazinamide 126, 128, 257  
 pyrimethamine 149–50

## Q

QRS intervals 37, 51, 273  
 QT intervals 13, 33, 37, 40  
 quality adjusted life years (QALY) 262, 264–7  
 quinagolide 167–8  
 quinidine 37  
 quinine 150, 152  
 quinolones 117, 124  
 quinupristin-dalfopristin 125

## R

RA *see* rheumatoid arthritis  
 RAAS *see* renin-angiotensin aldosterone system  
 rabeprazole 20  
 radioactive iodine therapy 161  
 ramipril 4  
 ranolazine 33  
 rasagiline 94  
 rasburicase 203  
 rashes 117  
 reactive arthritis 197  
 rebound symptoms 290  
 receptor sensitivity 254  
 receptors and drug action 4–5  
 recombinant erythropoietin 225  
 recombinant G-CSF 225  
 recombinant tPA 223  
 rectal diazepam 286  
 redox processes 8–9  
 regional anaesthesia 233–5  
 remidentanil 233  
 renal excretion 10  
 renal function  
 antimicrobial therapy 113, 116  
 cardiovascular disease 59–60  
 elderly patients 254  
 hypertension 54

- renal function (*continued*)
    - pharmacokinetics 247–9
    - toxicology 282
  - renal stones 137
  - renin-angiotensin aldosterone system (RAAS) 44, 46, 59–61
  - reproductive system 169–77
    - anti-progestogen 174
    - hormonal contraception 169–73
    - menopausal symptoms 173–4, 176–7
    - non-contraceptive uses of progestogens 174
    - ovulation-induction 176–7
    - pregnancy 174–5
    - uterine and cervical modification 174–5
  - resistance *see* drug resistance
  - resource scarcity 262
  - respiratory acidosis 273
  - respiratory alkalosis 273
  - respiratory disease 71–80
    - asthma 71–8
    - bronchiectasis 78–9
    - chronic obstructive pulmonary disease 71–8
    - cystic fibrosis 79
    - interstitial lung disease 79
    - pulmonary hypertension 79–80
  - reteplase 223
  - reverse transcriptase (RT) 132–3
  - rheumatoid arthritis (RA) 197, 206–8, 210–13
  - ribavirin 131
  - rifampicin 117, 126–8, 257
  - risendronate 165
  - ritodrine 175
  - rituximab 211, 213
  - rivaroxaban 223
  - rivastigmine 110
  - ropinirole 94
  - ropivacaine 234, 235
  - rotigotine 94
  - RT *see* reverse transcriptase
- S**
- SA *see* sinoatrial
  - SABA *see* short-acting  $\beta_2$ -agonists
  - safety studies 13
  - salbutamol 72, 76–7, 175
  - salicylates
    - inflammatory joint disease 198
    - malignancies 191
    - toxicology 278–9
    - see also* aspirin
  - salmeterol 72
  - sanctuary sites 189
  - saxagliptin 158
  - schizophrenia 97
  - secondary cancers 190
  - secondary dyslipidaemias 64–5
  - secondary hypertension 54
  - sedatives 278
  - seizures 274
  - selective noradrenaline reuptake inhibitors (SNRI) 174
  - selective oestrogen-receptor modulators (SERMS) 166
  - selective progesterone receptor modulator (SPRM) 169
  - selective serotonin reuptake inhibitors (SSRI)
    - gastrointestinal disease 25
    - pregnancy 260
    - psychiatric disorders 97, 101–2, 106
    - reproductive system 174
    - toxicology 273, 276
  - selective sinus node inhibitors 32–3
  - selegiline 94
  - sensitivity analysis 267
  - SERMS *see* selective oestrogen-receptor modulators
  - serotonin agonists 26, 87, 106
  - serotonin antagonists 24
  - serotonin and noradrenaline reuptake inhibitors (SNRI) 103
  - serum concentrations 243
  - sexual disorders 92, 182–4
  - short-acting  $\beta_2$ -agonists (SABA) 72–3
  - short-burst oxygen therapy 78
  - side effects *see* adverse drug reactions
  - sideroblastic anaemia 226
  - signal transduction pathways 191–2
  - sildenafil 182
  - simvastatin 9
  - single intravenous bolus doses 7–8
  - sinoatrial (SA) nodes 35, 37, 39–40
  - siromilus 207
  - sitagliptin 158
  - SJS *see* Stevens-Johnson syndrome
  - SLE *see* systemic lupus erythematosus
  - sleep disorders 91, 106–7
  - smoking 52, 71, 77–8
  - SNRI *see* serotonin and noradrenaline reuptake inhibitors
  - sodium cromoglicate 76
  - sodium fucidate 123
  - sodium nitroprusside 49, 64
  - sodium valproate *see* valproic acid/valproate
  - somatic pain 229
  - somatostatin analogues 168
  - sotalol 40
  - spasticity 92
  - SPC *see* summary of product characteristics
  - spironolactone 45, 47
  - SPRM *see* selective progesterone receptor modulator
  - SSRI *see* selective serotonin reuptake inhibitors
  - ST segment elevation myocardial infarction (STEMI) 30, 223
  - stable angina 29–30, 33–4
  - standard gamble technique 266
  - statins 9
    - cardiovascular disease 65–6
    - neurological disease 90
    - pregnancy 259
  - status epilepticus 82, 285–6
  - steady-state concentrations 6–7
  - steroid-sparing agents 76
  - steroids *see* corticosteroids
  - Stevens-Johnson syndrome (SJS) 117, 137

stimulant laxatives 25  
 stool softeners 25  
 streptokinase 223  
 streptomycin 128, 257  
 stroke 52, 89–90, 91, 171  
 strontium ranelate 167  
 substance use disorders 97, 108–10, 281  
 sucralfate 22  
 suicidality 97  
 sulfadoxine 150, 152  
 sulfasalazine 200–1, 206, 211  
 sulfinpyrazone 203  
 sulfonyleureas 156–7  
 sulphation 9  
 sulphonamides 115, 117, 121–2  
 sumatriptan 88  
 summary of product characteristics (SPC) 14  
 supraventricular tachycardia 284–5  
 suxamethonium 237  
 systemic lupus erythematosus (SLE) 85, 197

## T

T-cell targeting agents 206–7, 211  
 T-helper cells 204–5, 206–7  
 tachycardia 274  
 tachypnoea 274  
 tacromilus 207  
 tadalafil 182  
 tamoxifen 176, 191  
 taxanes 188–9  
 TCA *see* tricyclic antidepressants  
 teicoplanin 124  
 tenectapase 223  
 teniposide 189  
 teratogenicity 255–6  
   blood conditions 222  
   chemotherapy 190  
   neurological disease 86  
 terbutaline 72  
 teriparatide 167  
 testicular cancer 194  
 testosterone therapy 183, 191  
 tetracaine 234  
 tetracyclines 117, 122, 256  
 thalidomide 11, 256  
 theophyllines 75, 77, 214, 242  
 therapeutic drug monitoring 241–2, 243–6  
 therapeutic index 5  
 thiazide diuretics 56–7  
 thiazolidinediones 157  
 thienopyridines 69  
 thionamide antithyroid drugs 160–1  
 thiopental/thiopentone 236  
 thiopurines 27  
 thiourylene antithyroid drugs 160–1  
 thrombin time 218  
 thrombocytopenia 116, 218–19, 222, 227  
 thrombolytic agents 223  
 thrombosis 67–70, 215, 216–17, 259  
 thyroid crisis 162  
 thyroid disease 160–2  
 thyrotoxicosis 160–2  
 TIA *see* transient ischaemic attack  
 ticagrelor 69  
 tigecycline 126  
 tiludronate 165  
 time trade-offs 266  
 tiotropium bromide 73  
 tiredness 62  
 tirofiban 70  
 tissue plasminogen activator (tPA) 216, 223  
 TNF *see* tumour necrosis factor  
 tocainide 37  
 tocilizumab 213  
 tocolytics 175  
 tolcapone 95  
 tolerance 205  
 topical steroids 210  
 topiramate 84, 86, 88  
 topoisomerase enzyme inhibitors 189  
 topotecan 188, 189  
 torasemide 44–5  
 torsades de pointes 39–40  
 TOXBASE 270, 279  
 toxicology 269–82  
   antidotes 277  
     assessment and diagnosis 270–2  
     drug development 12  
     emergency treatments 286  
     enhanced drug elimination 275  
     general approach to poisoned patient 270–4  
     haemodialysis 275–6  
     haemoperfusion 276  
     hepatic function 280–1  
     immediate management 273–4  
     management of specific complications 274–5  
     overdose 269, 276–82  
     pharmacokinetics 275  
     physiological support systems 276  
     poisoning 269–76  
     specific treatments 275  
     substance abuse 281  
     toxicological analyses 272–3  
 tPA *see* tissue plasminogen activator  
 tramadol 233  
 transient ischaemic attack (TIA) 89  
 translational research 15  
 trastuzumab 193–4  
 tremors 90  
 triamcinolone 210  
 triamterene 56  
 tricyclic antidepressants (TCA)  
   gastrointestinal disease 25  
   pregnancy 260  
   psychiatric disorders 97, 101–2, 106  
   toxicology 276



triglycerides 57, 66–7  
 trihexiphenidyl 94  
 trimethoprim 121–2  
 triptans 26, 87, 106  
 tropical diseases 143–52
 

- antimicrobial therapy 151
- chemoprophylaxis 143, 148–52
- disease risk areas for malaria 148
- helminthic infections 151, 152
- immunisation principles 143–7
- life cycle of malaria 147–8
- malaria prevention and treatment 147–52
- parasitic infections 151, 152
- risk assessments 145
- vaccine contraindications 147

 tuberculous infections 126–8  
 tumour necrosis factor (TNF) 212–13  
 tumours *see* malignancies  
 type I diabetes 153, 257  
 type II diabetes 3, 153, 257  
 type II topoisomerase inhibitors 182  
 tyrosine kinase inhibitors 213

## U

UIP *see* usual interstitial pneumonia  
 ulipristal acetate (UPA) 170  
 unfractionated heparin 217–18  
 unstable angina 30, 34  
 UPA *see* ulipristal acetate  
 uraemia 248  
 uricosuric drugs 203  
 urological system 178–84
 

- bladder outlet obstruction 178–9
- erectile dysfunction 182–4
- overactive bladder 179–80
- prostate cancer 181–2

 ustekinumab 213  
 usual interstitial pneumonia (UIP) 79  
 uterine modification 174–5  
 utility values 265–6

## V

vaccination 143–7  
 valaciclovir 130  
 valproic acid/valproate
 

- neurological disease 84, 85, 88
- pregnancy 256–7, 258
- psychiatric disorders 104

 valsartan 60–1  
 vancomycin 124

varденаfil 182  
 varenicline 78  
 venlafaxine 88, 103, 174  
 venous thromboembolic disease (VTE) 170–1, 174, 259  
 ventricular myocardium 35  
 verapamil 31–2, 34, 40, 58–9  
 very low-density lipoprotein (VLDL) cholesterol 67  
 vildagliptin 158  
 vinca alkaloids 188  
 viral infections 114, 130–1  
 visceral pain 229  
 visual analogue scales 266  
 vitamin B<sub>12</sub> 224–5  
 vitamin D compounds 164  
 vitamin deficiency 109, 110  
 vitamin K antagonists 219–22  
 volume of distribution 6  
 vomiting *see* nausea and vomiting  
 voriconazole 129  
 VTE *see* venous thromboembolic disease

## W

warfarin 219–22
 

- coronary artery disease 40
- inflammatory joint disease 199
- neurological disease 89
- pregnancy 256, 259

 weight gain 156  
 WHO analgesic ladder 229  
 whole bowel irrigation 273  
 withdrawal symptoms 109, 290  
 Wolff–Parkinson–White syndrome 37–8

## X

xanthine oxidase inhibitors 202, 203

## Y

yellow card scheme 15

## Z

zafirlukast 74–5  
 zaleplon 107  
 zanamivir 131  
 zidovudine 132–5  
 zolendronate 165  
 zolpidem 107  
 zopiclone 107